Faust Pharmaceuticals has completed a Phase IIa clinical trial of its lead molecule,
FP0011, in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The
results observed in patients showed the antiglutamatergic drug was safe and
well-tolerated,
The goal of the trial was to acquire data on FP0011 patient tolerance and safety,
and to check whether it was possible to administer FP0011 in combination with
riluzole, currently the only ALS treatment on the market. The trial showed that
FP0011, administered for one month at the doses of 60 and 120mg per day, did
not modify plasma concentrations of riluzole, and displayed an excellent clinical
and biological safety.
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Devicemakers Pay $9.5 Million for Selling Uncleared Products
The FDA hit Instrumed with a warning letter in 2014.
Federal Circuit Won’t Rehear Purdue Pharma’s OxyContin Patent Claims
The U.S. Court of Appeals for the Federal Circuit turned down Purdue’s appeal and upheld the PTAB ruling.
